It may inhibit erythropoiesis by interfering with intracellular signaling pathways normally activated after the binding of erythropoietin to its receptor, resulting in anemia, thrombocytopenia, and leucopenia (Fang et al., 2007). The gene discussed is EPO; the disease is anemia (phenotype).